Compare Google Inc (GOOG) vs TG Therapeutics Inc (TGTX) Price & Performance

Alphabet (GOOG) trades at $344.86, down 0.72% on the day, with strong technical support at $342 and resistance at $348. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $435.24 consensus price target, representing 26% upside potential.

The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors should monitor elevated capital expenditures and potential regulatory risks. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, with upcoming Q3 earnings on October 31, 2026, serving as the next key catalyst.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.